JOHN KORTVELESY, M.D.
Ophthalmology Physician in HONOLULU, Hawaii. CMS National Plan and Provider Enumeration System profile including specialty classification, practice address, and Medicare prescribing data when reported.
What the federal data shows
JOHN KORTVELESY, M.D. reported a CMS MIPS final score of 86.203/100 — above the 83.1 national average — and filed 745 Medicare Part D claims in 2023.
- 86.203/100
- MIPS score · +3 vs avg
- 745
- Part D claims, 2023
- 50%
- generic prescribing
- Likely
- board-certified (heuristic)
Every figure on this page comes straight from federal CMS records (NPPES, Medicare Part D, MIPS, Open Payments) — no proprietary rating or editorial opinion is applied.
JOHN KORTVELESY, M.D.'s MIPS score vs every scored U.S. clinician
CMS Merit-based Incentive Payment System (MIPS) final score, 2023 — the federal quality measure
86 Top 48% higher than 52% of 477,587 scored providers
Each bar is a band; taller bars hold more scored providers. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.
Source CMS Merit-based Incentive Payment System (MIPS) · 2023
JOHN KORTVELESY, M.D. practices in an ABMS-board-eligible specialty and shows active CMS Medicare participation + MIPS quality reporting — signals consistent with board-certified status. For verified board certification, see CertificationMatters.org (the official ABMS public lookup).
What does the federal data show about JOHN KORTVELESY, M.D.?
High performer (top quartile)Primary specialty
Medicare Part D claims
MIPS final score
Specialty distribution in Hawaii
How Ophthalmology Physician compares to other specialties among Hawaii providers
Ophthalmology Physician share within Hawaii
Ophthalmology Physician is one of the more visible NUCC categories in Hawaii
Each bar reflects the share of in-state providers whose primary NUCC taxonomy matches the specialty. Long tail of ~690 NUCC codes folded into "Other" to keep the comparison legible.
Medicare quality performance — MIPS
JOHN KORTVELESY, M.D.'s 2023 MIPS final score plotted against the Ophthalmology Physician national average
- MIPS Final Score
- 86.203/100
- vs 83.1 national avg · 2023 performance year
MIPS final score (Ophthalmology Physician) — 86.203/100 vs national avg 83.1
Quality benchmarks
- National MIPS avg 2023 reporting year
- Quality dim CMS Quality category
- Cost dim CMS Cost category
- Specialty volume Ophthalmology Physician US NPIs
86.203/100 MIPS final score — 3.1 pts above the 83.1 national average
Quality, Cost, Promoting Interoperability, and Improvement Activities composite score for the 2023 performance year. Specialty: Ophthalmology Physician. Quality dim: 80.286. Cost dim: 73.7239.
The Merit-based Incentive Payment System (MIPS) scores providers 0–100 across four performance categories: Quality, Cost, Promoting Interoperability, and Improvement Activities, weighted under 42 CFR §414.1380. Reporting is voluntary for many small practices, so absence of a MIPS score is not a quality signal.
Board certification through an ABMS or AOA member board signals voluntary post-licensure examination plus continuous Maintenance of Certification cycles. Verify any individual provider's status through certificationmatters.org (ABMS) or osteopathic.org (AOA).
JOHN KORTVELESY, M.D. appears in the CMS NPPES registry as a Ophthalmology Physician provider holding M.D. credentials at 888 S KING ST, HONOLULU, HI, 96813, with a listed phone of (808) 522-4430. NPI 1710082813 was issued on 09/13/2006. Because NPPES data is self-reported by the provider and refreshed monthly, the address, phone, and specialty reflect what KORTVELESY most recently submitted to CMS rather than a vetted directory listing, which is why patients should always confirm the practice is still at this location before scheduling.
Medicare Part D records for calendar year 2023 show 745 prescription claims written by this provider, covering 228 Medicare beneficiaries and totaling roughly $334K in drug spend, split 50% brand-name and 50% generic by claim count. These figures capture only Medicare Part D — commercial insurance, Medicaid, and cash-pay prescriptions are not included, and any drug-beneficiary cell under 11 is suppressed by CMS for patient privacy. On the CMS Merit-based Incentive Payment System, this provider earned a Final Score of 86.203/100 for the 2023 performance year (Quality 80.286, Cost 73.7239), compared with the national average of 83.1.
Ophthalmology Physician is a mid-sized specialty nationwide, with 22,090 enrolled providers across 56 states and an average of 1,420 Part D claims per prescriber, so the context for interpreting these metrics differs meaningfully from a primary-care baseline. Important: PlainDoctor is a directory of publicly available government data, not medical advice, a malpractice database, or a quality rating. Inclusion here does not imply a recommendation, and absence of complaints or sanctions on this page does not mean none exist — always verify credentials through the NPPES NPI Registry, your state medical board, and the ABMS or AOA before making healthcare decisions.
Practice Address
Provider Details
| NPI | 1710082813 |
|---|---|
| Specialty | Ophthalmology Physician |
| Credentials | M.D. |
| Gender | Male |
| NPI Issued | 09/13/2006 |
Verify this provider's license
PlainDoctor pulls this profile from the CMS NPPES public registry. Confirm JOHN KORTVELESY, M.D.'s current license status, disciplinary history, and board certifications with the Hawaii Medical Board in Hawaii before relying on this page for a clinical or care decision.
How we sourced this profile
CMS Quality Score (MIPS)
Merit-based Incentive Payment System (MIPS) scores from CMS, 2023 performance year.
Reporting: Group practice
Industry payments received (2024) — CMS Open Payments transparency data
The federal Physician Payments Sunshine Act (part of the Affordable Care Act) requires drug and medical-device manufacturers + group purchasing organizations to publicly report payments and other transfers of value to physicians and teaching hospitals. The data below covers 2024 for JOHN KORTVELESY, M.D.. Source: openpaymentsdata.cms.gov.
Total received
$1.2K
Largest payer
Amgen Inc.
Most common payment type
Food and Beverage
Industry payments are not necessarily indicators of bias — they include research funding, consulting fees for evidence-based work, royalties for inventions, food at conferences, and similar items. The disclosure exists for transparency. Read our methodology for how we interpret this data.
Brand vs generic prescribing mix · Brand-heavy
50% brand-name claims vs 50% generic, on 745 2023 Medicare Part D claims.
The federal Medicare Part D Generic Dispensing Rate national benchmark sits near 90% generic / 10% brand for primary-care prescribers, per CMS Office of the Actuary 2024 estimates. Higher brand share is common in specialty prescribing where generic equivalents are not available.
Medicare Part D Prescribing Data
CMS Medicare Part D prescriber-level data for calendar year 2023.
Prescribing Breakdown
- 30-Day Fills
- 1,503
- Total Day Supply
- 43,281
- Brand vs Generic
- 50% brand / 50% generic
- Brand Drug Cost
- $314K
- Generic Drug Cost
- $19K
Patient Demographics
- Average Patient Age
- 78.1 years
- Avg HCC Risk Score
- 1.26
- Gender Split
- 62% female / 38% male
Top Prescribed Drugs (Medicare Part D)
Top drugs by claim count for calendar year 2023. Based on Medicare Part D data only.
What JOHN KORTVELESY, M.D. prescribes most
Top Medicare Part D drugs by claim count, 2023
- Latanoprost
Latanoprost
235 claims
- Timolol Maleate 64
Timolol Maleate
64 claims
- Brimonidine Tartrate 36
Brimonidine Tartrate
36 claims
- Prednisone 34
Prednisone
34 claims
- Neomycin-Polymyxin… 27
Neomycin-Polymyxin-Dexameth
27 claims
- Ketorolac Trometha… 26
Ketorolac Tromethamine
26 claims
- Restasis 25
Restasis
25 claims
- Dorzolamide-Timolol 24
Dorzolamide-Timolol
24 claims
| Drug | Claims |
|---|---|
| Latanoprost | 235 |
| Timolol Maleate | 64 |
| Brimonidine Tartrate | 36 |
| Prednisone | 34 |
| Neomycin-Polymyxin-Dexameth Neomycin/Polymyxin B/Dexametha | 27 |
| Ketorolac Tromethamine | 26 |
| Restasis Cyclosporine | 25 |
| Dorzolamide-Timolol Dorzolamide Hcl/Timolol Maleat | 24 |
| Travoprost | 17 |
| Prednisolone Acetate | 16 |
* Counts below 11 are suppressed by CMS for patient privacy. Generic names shown where available from CMS Part D data.
Ophthalmology Physician Overview
How JOHN KORTVELESY, M.D. fits within the Ophthalmology Physician landscape nationally.
JOHN KORTVELESY, M.D.'s 745 claims are below the specialty average of 1,420.
Nearby Ophthalmology Physician Providers in Hawaii
Other clinicians with the same primary specialty enrolled in Hawaii, drawn from the same CMS NPPES roster as KORTVELESY.
Compare Ophthalmology Physician nationally: see state-by-state distribution →
Healthcare Guides
Learn more about finding, verifying, and understanding healthcare providers.
Explore Hawaii
Frequently Asked Questions
What is JOHN KORTVELESY, M.D.'s specialty? ▼
How much does JOHN KORTVELESY, M.D. prescribe under Medicare Part D? ▼
What is JOHN KORTVELESY, M.D.'s Medicare quality score? ▼
Where is JOHN KORTVELESY, M.D. located? ▼
What is JOHN KORTVELESY, M.D.'s NPI number? ▼
Does JOHN KORTVELESY, M.D. prescribe more brand-name or generic drugs? ▼
How many Ophthalmology Physician providers are there in the US? ▼
What drugs does JOHN KORTVELESY, M.D. prescribe most often? ▼
Does JOHN KORTVELESY, M.D. accept Medicare? ▼
How can I verify JOHN KORTVELESY, M.D.'s credentials? ▼
Data Sources
- Provider Directory
- CMS National Plan and Provider Enumeration System (NPPES), download.cms.gov/nppes, updated monthly. Contains NPI, specialty, credentials, and practice location.
- Specialty Classification
- NUCC Health Care Provider Taxonomy (nucc.org), the industry standard for classifying provider specialties in Medicare and Medicaid billing.
- Prescribing Data
- CMS Medicare Part D Prescriber Public Use File (2023). Includes claims, drug costs, beneficiaries, and opioid prescribing rates.
- Quality Performance
- CMS Merit-based Incentive Payment System (MIPS) — 2023 performance year.
- Limitations
- Provider data is self-reported to CMS. Prescribing data reflects Medicare Part D only and does not include commercial insurance, Medicaid, or cash prescriptions. Claims below 11 beneficiaries are suppressed by CMS for privacy.
See our complete data methodology for details on how we collect and process government data.
Data as of April 2026 (NPPES) / 2023 (Medicare Part D). Source: Centers for Medicare & Medicaid Services (CMS).
Disclaimer: Data from CMS NPPES and Medicare Part D. PlainDoctor does not rate or rank providers. Provider information is self-reported and may not be current. Always verify information directly with the provider. About · Methodology